Open Actively Recruiting

A Study of LOXO-435 in Patients With Cancer With a Change in a Gene Called FGFR3


Brief Summary

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.

Primary Purpose
Study Type


Healthy Volunteers
Minimum Age
18 Years
Maximum Age

Inclusion Criteria:

  • Have solid tumor cancer with an FGFR3 pathway alteration on molecular testing in tumor or blood sample that is deemed as actionable.
    • Cohort A (Dose Escalation): Presence of an alteration in FGFR3 or its ligands deemed as a clinically or potentially clinically relevant alteration by the treating Investigator.
    • Cohorts B1, B2 and B3 (Dose Expansion): Histological diagnosis of urothelial cancer that is locally advanced or metastatic with a prespecified activating FGFR3 alteration.
    • Cohort C (Dose Expansion): Must have histological diagnosis of a non-urothelial solid tumor malignancy that is locally advanced or metastatic with a prespecified activating FGFR3 alteration.
  • Measurability of disease:
    • Phase 1a: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v1.1)
    • Phase 1b: Measurable disease required as defined by RECIST v1.1
  • Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country-specific regulations.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Patient has received all standard therapies for which the patient was deemed to be an appropriate candidate by the treating Investigator; OR the patient is refusing the remaining most appropriate standard of care treatment; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies.
    • Cohort B1: Patients must have been previously treated with a FGFR inhibitor.
    • Cohort B2, B3, C1: Patients must be FGFR inhibitor naïve.

Exclusion Criteria:

  • Patients with primary central nervous system (CNS) malignancy
  • Known or suspected history of uncontrolled CNS metastases
  • Current evidence of corneal keratopathy or retinal disorder
  • Have a history and/or current evidence of extensive tissue calcification
  • Any serious unresolved toxicities from prior therapy
  • Significant cardiovascular disease
  • Prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF)
  • Active uncontrolled systemic infection or other clinically significant medical conditions
  • Patients who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
Bladder Cancer
Sandy Hernandez Centeno
  • UCLA Burbank
  • UCLA Encino
  • UCLA San Luis Obispo
  • UCLA Santa Barbara
  • UCLA Santa Monica
  • UCLA Torrance
  • UCLA Ventura
  • UCLA Westlake Village
For Providers
For detailed technical eligibility, visit